References

ppharm

Педиатрическая фармакология

Pediatric pharmacology

1727-57762500-3089

Издательство «ПедиатрЪ»

10.15690/pf.v10i4.750

ppharm-191

Research Article

ВАКЦИНАЦИЯ В СОВРЕМЕННОМ МИРЕ

VACCINATION

ИММУНОПРОФИЛАКТИКА РЕСПИРАТОРНО-СИНЦИТИАЛЬНОЙ ВИРУСНОЙ ИНФЕКЦИИ: 15 ЛЕТ МИРОВОГО ОПЫТА

IMMUNE PREVENTION OF RESPIRATORY-SYNCYTIAL VIRAL INFECTION: 15 YEARS OF WORLD EXPERIENCE

Кешишян

Е. С.

Keshishyan

E. S.

доктор медицинских наук, профессор, руководитель научного отдела неонатологии и патологии детейраннего возраста, руководитель Научно-практического центра коррекции развития недоношенных детей Московского НИИ педиатрии и детской хирургии

PhD, Professor, head of the scientific department of neonatology and infant pathology, head of the theoretical-and-practical development correction center for premature infants at the Moscow Research Institute of Pediatrics and Pediatric Surgery

info@rastim-baby.ru

Московский научно-исследовательский институт педиатрии и детской хирургии МЗ РФРоссияMoscow Research Institute of Pediatrics and Pediatric Surgery of the Ministry of Health of the RFRussian Federation

2013

14082013

104

Педиатрическая фармакология

614

2013

Кешишян Е.С.

Keshishyan E.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pedpharma.ru/jour/article/view/191

The article is dedicated to one of the most important issues of modern neonatology – prevention of respiratory-syncytial virus infection, which is a frequent cause of bronchiolites and pneumoniae in infants and neonates, especially premature infants. The latter belong to the high-risk group for the development of this infection with unfavorable outcome. The authors present detailed data on epidemiology and world spread of respiratory-syncytial virus infection, its consequences (short-term and long-term) and prevention possibilities. The authors demonstrate efficacy of passive palivizumab (humanized monoclonal antibody) immune prevention on the basis of multiple studies conducted in different countries. The authors show the process of formation of national recommendations for immune prevention of development of this infection. Apart from the main risk groups for the development of respiratory-syncytial virus infection, acknowledged by the scientists, the authors also present additional groups – children with mucoviscidosis, Down’s syndrome, neuromuscular diseases and immune compromised patients due to the primary immune deficiency or in the setting of immune suppressive therapy.

респираторно-синцитиальная вирусная инфекциязаболеваемостьсмертностьгруппы рисканедоношенные детииммунопрофилактикапавилизумабэффективностьбезопасностьнациональные рекомендации

respiratory-syncytial virus infectionepidemiologymorbidityconsequencesrisk groupspreventionpalivizumabefficacysafetychildrenneonatespremature infants

References1

Nair H., Nokes D. J., Gessner B. D. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet. 2010; 375 (9725): 1545–1555.

Johnson S., Oliver C., Prince G. A. et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997; 176: 1215–24.

Shay D. K., Holman R. C., Newman R. D. et al. Bronchiolitisassociated hospitalizations among US children, 1980–1996. JAMA. 1999; 282: 1440–6.

Stensballe L. G., Devasundaram J. K., Simoes E. A. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr Infect Dis J. 2003; 22 (2 Suppl.): 21–32.

Stensballe L. G., Devasundaram J. K., Simoes E. A. Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus. Pediatr. Infect. Dis. J. 2003; 22 (2 Suppl.): 21–32.

URL: http://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html

Available at: http://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html

Lanari M., Giovannini M., Giuffre L. et al. Investigators RADAR Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol. 2002; 33: 458–465.

Rossi G. A., Medici M. C., Arcangeletti M. C. et al. Osservatorio RSV Study Group. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr. 2007; 166: 1267–1272.

Tatochenko V., Uchaikin V., Gorelov A. et al. Epidemiology of respiratory syncytial virus in children _ 2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin Epidemiol. 2010 Oct 21; 2: 221–7.

Tatochenko V., Uchaikin V., Gorelov A. et al. Epidemiology of respiratory syncytial virus in children more or about 2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clin. Epidemiol. 2010 Oct 21; 2: 221–7.

Намазова-Баранова Л.С., Давыдова И.В., Турти Т.В. Принципы пассивной иммунизации паливизумабом детей группы риска тяжелого течения РСВ-инфекции. Фарматека для практикующих врачей. 2013; 1: 51–55.

Namazova-Baranova L.S., Davydova I.V., Turti T.V. Farmateka dlya praktikuyushchikh vrachei = Pharmateca for practicing physicians. 2013; 1: 51–55.

Отчет «Мониторинг РС-вирусной инфекции среди детей 0–2 лет по данным традиционного и сигнального надзора за период с 52 недели 2012 г. по 17 неделю 2013 г. ФГБУ «НИИ гриппа» Минздрава России. СПб., 2013.

Otchet «Monitoring RS-virusnoi infektsii sredi detei 0–2 let po dannym traditsionnogo i signal'nogo nadzora za period s 52 nedeli 2012 g. po 17 nedelyu 2013 g. FGBU «NII grippa» Minzdrava Rossii [The Report "Monitoring of RS-Virus Infection among Children of 0-2 years according to the Traditional Signaling and Supervision for the Period from 52nd week of 2012 to 17th week of 2013 FSBI "Influenza Research Institute” of Russian Ministry of Health]. St.Petersburg, 2013.

Stockman L. J., Curns A. T., Anderson L. J. et al. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006. The Pediatric Infectious Disease Journal. 2012; 31 (1): 5–9.

Bourgeois F. T., Valim C., McAdam A. J. et al. Relative impact of influenza and respiratory syncytial virus in young children. Pediatrics. 2009; 124 (6): 1072–80.

Thompson W. W., Shay D. K., Weintraub E. et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003; 289: 179–186.

Овсянников Д. Ю. Острый бронхиолит у детей. Вопросы практической педиатрии. 2010; 5 (2): 75–84.

Ovsyannikov D. Yu. Acute bronchiolitis in children. Voprosy prakticheskoi pediatrii = Current pediatrics. 2010; 5 (2): 75–84.

Welliver R. C., Checchia P. A., Bauman J. H. et al. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Current Medical Research and Opinion. 2010; 26 (9): 2175–2181.

Holman R. C., Shay D. K., Curns A. T. et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J. 2003; 22: 483–490.

Holman R. C., Shay D. K., Curns A. T. et al. Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr. Infect. Dis. J. 2003; 22: 483–490.

Boukhvalova M. S., Prince G. A., Soroush L. et al. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine–enhanced disease. Vaccine. 2006; 24 (23): 5027–5035.

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics. 1997; 99 (1): 93–99.

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998; 102 (3 Pt. 1): 531–537.

Feltes T. F., Cabalka A. K., Meissner H. C. et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003; 143 (4): 532–540.

Pedraz C., Carbonell-Estrany X., Figueras-Aloy J. et al. Iris Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalisations in premature infants. Pediatr Infect Dis J. 2003; 22 (9): 823–827.

Checchia P. A., Nalysnyk L., Fernandes A. W. et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011; 12 (5): 580–588.

Sampalis J. S. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr. 2003; 143 (5 Suppl.): 150–6.

Sampalis J. S. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J. Pediatr. 2003; 143 (5 Suppl.): 150–156.

Sigurs N., Aljassim F., Kjellman B. et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010; 65 (12): 1045–1052.

Simoes E. A. F., Groothuis J. R., Carbonell-Estrany X. et al. Palivizumab prophylaxis, respiratory syncytial virus and subsequent recurrent wheezing. J Pediatr. 2007; 151: 34–42.

Simoes E. A. F., Groothuis J. R., Carbonell-Estrany X. et al. Palivizumab prophylaxis, respiratory syncytial virus and subsequent recurrent wheezing. J. Pediatr. 2007; 151: 34–42.

Blanken M. O., Rovers M. M., Molenaar J. M. et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013; 368 (19): 1791–1799.

Ibara S. Expanding boundaries: new risk groups for RSV prevention. XI World Congress of Perinatal Medicine. Moscow. 2013.

Figueras-Aloy J., Carbonell-Estrany X., Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J. 2004; 23 (9): 815–820.

Figueras-Aloy J., Carbonell-Estrany X., Quero-Jimenez J. et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008; 27 (9): 788–793.

Hall C. B., Powell K. R., MacDonald N. E. et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986; 315 (2): 77–81.

Hall C. B., Powell K. R., MacDonald N. E. et al. Respiratory syncytial viral infection in children with compromised immune function. N. Engl. J. Med. 1986; 315 (2): 77–81.

Manzoni P., Leonessa M., Farina D. et al. Respiratory syncytial virus infection and prophylaxis with palivizumab in immunosuppressed children: the experience of a large Italian neonatal care setting. Pediatr Transplant. 2007; 11 (4): 456–457.

Michaels M. G., Fonseca-Aten M., Green M. et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant. 2009; 13 (4): 451–456.

Michaels M. G., Fonseca-Aten M., Green M. et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr. Transplant. 2009; 13 (4): 451–456.

Hiatt P. W., Grace S. C., Kozinetz C. A. et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics. 1999; 103 (3): 619–626.

Giebels K., Marcotte J-E., Podoba J. et al. Prophylaxis againstrespiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol. 2008; 43 (2): 169–174.

Giebels K., Marcotte J-E., Podoba J. et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr. Pulmonol. 2008; 43 (2): 169–174.

Томилова А.Ю., Намазова-Баранова Л.С., Алексеева А.А., Давыдова И.В., Геворкян А.К., Вишнева Е.А., Вознесенская Н.И. Опыт применения паливизумаба у больной с муковисцидозом. V Российский Форум «Педиатрия Санкт-Петербурга: опыт, инновации, достижения. Санкт-Петербург–2013». Сборник тезисов. С. 119.

Tomilova A.Yu., Namazova-Baranova L.S., Alekseeva A.A., Davydova I.V., Gevorkyan A.K., Vishneva E.A., Voznesenskaya N.I. Opyt primeneniya palivizumaba u bol'noi s mukovistsidozom. V Rossiiskii Forum «Pediatriya Sankt-Peterburga: opyt, innovatsii, dostizheniya. Sankt-Peterburg–2013». Sbornik tezisov [Experience of Palivizumab Application in a Patient with Cystic Fibrosis. 5th Russian Forum "St. Petersburg’s Pediatrics: Experience, Innovations and Achievements. St. Petersburg-2013 ". Collection of Abstracts.]. St. Petersburg, 2013. p. 119.

Megged O., Schlesinger Y. Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J. 2010; 29 (7): 672–673.

Megged O., Schlesinger Y. Down syndrome and respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 2010; 29 (7): 672–673.

Resch B., Manzoni P., Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev. 2009; 10 (3): 148–153.

Resch B., Manzoni P., Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr. Respir. Rev. 2009; 10 (3): 148–153.

From the American Academy of Pediatrics: Policy statements — Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009; 124 (6): 1694–701.

From the American Academy of Pediatrics: Policy statements = Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009; 124 (6): 1694–701.

Turti T. V., Baibarina E. N., Degtiareva E. A. et al. A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation. BMC Research Notes. 2012; 5: 484.

Намазова-Баранова Л.С., Вишнева Е.А., Торшхоева Р.М., Куличенко Т.В., Томилова А.Ю., Алексеева А.А., Турти Т.В. Паливизумаб: новые возможности профилактики астмы? Педиатрическая фармакология. 2011; 8 (3): 24–30.

Namazova-Baranova L.S., Vishneva E.A., Torshkhoeva R.M., Kulichenko T.V., Tomilova A.Yu., Alekseeva A.A., Turti T.V. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2011; 8 (3): 24–30.

Корсунский А. А., Овсянников Д. Ю., Дегтярев Д. Н. и др. Иммуно профилактика респираторно-синцитиальной вирусной инфекции у детей групп риска тяжелого течения: первые результаты реализации Московской программы. Педиатрическая фармакология. 2012; 9 (3): 22–30.

Korsunskii A. A., Ovsyannikov D. Yu., Degtyarev D. N. et al. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (3): 22–30.

Рудакова А. В., Бабаченко И. В., Ровный В. Б. и др. Эффективность затрат на профилактику тяжелой респираторно-синци ти альной инфекции паливизумабом у недоношенных детей первого года жизни. Вопросы современной педиатрии. 2012; 11 (4): 80–84.

Rudakova A. V., Babachenko I. V., Rovnyi V. B. et al. Voprosy sovremennoi pediatrii = Current pediatrics. 2012; 11 (4): 80–84.

Давыдова И. В., Турти Т. В., Намазова-Баранова Л. С. и др. Имму нопрофилактика тяжелого течения респираторно-синцитиаль ной вирусной инфекции у детей с бронхолегочной дисплазией: результаты четырех эпидемических сезонов. Педиатрическая фармакология. 2012; 9 (6): 48–52.

Davydova I. V., Turti T. V., Namazova-Baranova L. S. et al. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9 (6): 48–52.

The authors declare that there are no conflicts of interest present.